Gene Techno Science Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020
November 05, 2019
Share
Gene Techno Science Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2020. For the year ending March 31, 2020, the company expects net sales of JPY 1,050 million, Operating loss of JPY 1,220 million, Ordinary loss of JPY 1,260 million, net loss of JPY 7,260 million or JPY 262.61 per share.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.